OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical trials that has demonstrated efficacy in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile.

prudect name : OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical trials that has demonstrated efficacy in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile.
OC000459

Synonyms: CAS NO: 851723-84-7Molecular Formula: C₂₁H₁₇FN₂O₂Molecular Weight: 348.37Purity: 98% minSolubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18538560